November MIMS update

Some of the recent changes to the medicines landscape, with new products, presentations, indications and contraindications New Products Elafibranor (Iqirvo) and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-α, PPAR-γ, and PPAR-δ in vitro. In vitro, both elafibranor and GFT1007 demonstrated 3 to 8 fold higher activity